2020年5月6日,美国食品和药物管理局(FDA)批准Tabrecta(Capmatinib)用于治疗成年患者的非小细胞肺癌(NSCLC)的已扩散到其他部位的身体。Tabrecta是首个获得FDA批准的具有特定突变(导致间充质-上皮转化或MET外显子14跳过的突变)的NSCLC疗法。 非小细胞肺癌(NSCLC)是一种在肺组织中形成恶性癌细胞的疾病。它是最常见的肺...
The FDA has granted an accelerated approval to capmatinib (Tabrecta) for patients with metastatic MET exon14 skipping (METex14)—mutated non—small cell lung cancer (NSCLC).1 The approval is based on primary findings from the phase II GEOMETRY mono-1 study (NCT02414139), in which capmatinib ...
CSA Schedule* Not a controlled drug N/A Loading... Approval History Drug history at FDA Loading... User Reviews & Ratings Review this drug Drugs.com Mobile App Access drug & treatment information, identify pills, check interactions and set up personal medication records. Download the Medication...
Medical Disclaimer Drug Status AvailabilityPrescription onlyRx Pregnancy & LactationRisk data available CSA Schedule* Not a controlled drug N/A Approval History Drug history at FDA